Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Issue 2 (28th January 2023)

• Record Type: Journal Article
• Authors: Wang, Peter Feng; Yee, Christopher W.; Gorsh, Boris; Zichlin, Miriam L.; Paka, Prani; Bhak, Rachel H.; Boytsov, Natalie; Khanal, Anamika; Noman, Ahmed; DerSarkissian, Maral; Ferrante, Shannon; Duh, Mei Sheng
• Is Part Of: Leukemia & lymphoma. Volume 64:Issue 2(2023)
• Page Start: 398
• Page End: 406
• Publication Date: 2023-01-28
• Subjects: Treatment patterns -- myeloma -- pharmacotherapeutics; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2140284
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Patients with relapsed/refractory multiple myeloma (RRMM) resistant to multiple drug classes remain a high unmet need population. This longitudinal retrospective cohort study assessed real-world treatment patterns and outcomes in adults with RRMM. Patients who had three or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (double-exposed) were further categorized as refractory to a PI and an immunomodulatory agent (double-class refractory, n = 381) or additionally to an anti-CD38 monoclonal antibody (triple-class refractory, n = 173). Treatment options are limited for patients with double-class or triple-class refractory disease. Retreatment is a part of standard of care. Bortezomib and lenalidomide had the highest retreatment rates among double-class and triple-class refractory patients. Survival outcomes remain poor among RRMM patients with median overall survival (OS) of 22.3 and 11.6 months for double-class refractory and triple-class refractory patients, respectively. This study highlights the need for novel efficacious therapies in this heavily pretreated RRMM population.